Dose–effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization

Publication date

2024-06

Authors

Ramdhani, Khalil
Beijer-Verduin, J.
Ebbers, S. C.
van Rooij, RobISNI 000000039182607X
Smits, Maarten L.J.ORCID 0000-0003-4735-655XISNI 0000000419580500
Bruijnen, Rutger C.G.
de Jong, Hugo W.A.M.ORCID 0000-0002-3000-8316
Lam, Marnix G.E.H.ORCID 0000-0002-4902-9790
Braat, Arthur J.A.T.ORCID 0000-0002-8824-8697

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Purpose: Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM) treated with holmium-166-microspheres radioembolization ([166Ho]-radioembolization). Materials and methods: Single center, retrospective study included patients with NELM that received [166Ho]-radioembolization with post-treatment SPECT/CT and CECT or MRI imaging for 3 months follow-up. Post-treatment SPECT/CT was used to calculate tumour (Dt) and whole liver healthy tissue (Dh) absorbed dose. Clinical and laboratory toxicity was graded by Common Terminology Criteria for Adverse Events (CTCAE), version 5 at baseline and three-months follow-up. Response was determined according to RECIST 1.1. The tumour and healthy doses was correlated to lesion-based objective response and patient-based toxicity. Kaplan Meier analyses were performed for progression free survival (PFS) and overall survival (OS). Results: Twenty-seven treatments in 25 patients were included, with a total of 114 tumours. Median follow-up was 14 months (3 – 82 months). Mean Dt in non-responders was 68 Gy versus 118 Gy in responders, p = 0.01. ROC analysis determined 86 Gy to have the highest sensitivity and specificity, resp. 83% and 81%. Achieving a Dt of ≥ 120 Gy provided the highest likelihood of response (90%) for obtaining response. Sixteen patients had grade 1–2 clinical toxicity and only one patient grade 3. No clear healthy liver dose-toxicity relationship was found. The median PFS was 15 months (95% CI [10.2;19.8]) and median OS was not reached. Conclusion: This study confirms the safety and efficacy of [166Ho]-radioembolization in NELM in a real-world setting. A clear dose–response relationship was demonstrated and future studies should aim at a Dt of ≥ 120 Gy, being predictive of response. No dose-toxicity relationship could be established.

Keywords

Holmium-166, Neuroendocrine liver metastases, Neuroendocrine tumour, Radioembolization, SIRT, Radiology Nuclear Medicine and imaging

Citation

Ramdhani, K, Beijer-Verduin, J, Ebbers, S C, van Rooij, R, Smits, M L J, Bruijnen, R C G, de Jong, H W A M, Lam, M G E H & Braat, A J A T 2024, 'Dose–effect relationships in neuroendocrine tumour liver metastases treated with [ 166 Ho]-radioembolization', European Journal of Nuclear Medicine and Molecular Imaging, vol. 51, no. 7, pp. 2114-2123. https://doi.org/10.1007/s00259-024-06645-6